MARKET

KZIA

KZIA

Kazia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.05
-0.15
-1.47%
After Hours: 10.29 +0.24 +2.39% 16:10 05/07 EDT
OPEN
10.33
PREV CLOSE
10.20
HIGH
10.36
LOW
9.80
VOLUME
54.51K
TURNOVER
--
52 WEEK HIGH
15.85
52 WEEK LOW
2.500
MARKET CAP
126.80M
P/E (TTM)
-9.2558
1D
5D
1M
3M
1Y
5Y
A Trio of Stocks With Solid Balance Sheets for the Value Investor
GuruFocus News · 1d ago
Kazia Therapeutics (ASX:KZA) Is In A Good Position To Deliver On Growth Plans
Simply Wall St. · 4d ago
The eggs files: why hens are at the centre of modern science
News, analysis and comment from the Financial Times, the worldʼs leading global business publication
Financial Times · 6d ago
Proactive news headlines including Chase Mining Corporation, Red River Resources, Aurumin and Kazia Therapeutics
Sydney, April 26, Apr 26, 2021 (GLOBE NEWSWIRE via COMTEX) -- Sydney, April 26, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video...
GlobeNewswire · 04/26 06:14
Kazia Therapeutics (KZIA): New asset to target tumor lymphangiogenesis
LONDON, UK / ACCESSWIRE / April 20, 2021 / Kazia announced that it is expanding its pipeline to include EVT801, a novel small molecule inhibitor of VEGFR3. The drug is being licensed from Evotec for €1m upfront, €308m in milestones and tiered single-digit ...
ACCESSWIRE · 04/20 16:35
Kazia Therapeutics Announced Worldwide Exclusive Licensing Deal & Master Services Deal With Evotec SE
Kazia Therapeutics Limited (NASDAQ: KZIA) is pleased to announce that it has entered into a worldwide exclusive licensing agreement and a master services agreement with Evotec SE (OTC: EVOTF), a leading European drug discovery and development company, for...
Benzinga · 04/19 09:17
Evotec teams up with Kazia Therapeutics for development of EVT801
Evotec SE (EVOTF) has entered into both a licensing and master service agreement with Kazia Therapeutics (KZIA).Under the contract, Evotec will grant Kazia an exclusive worldwide license for research, development
Seekingalpha · 04/19 08:58
Kazia Therapeutics Licenses Global Rights to Evotec's EVT801
MT Newswires · 04/19 06:06
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KZIA. Analyze the recent business situations of Kazia through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KZIA stock price target is 17.12 with a high estimate of 17.12 and a low estimate of 17.12.
EPS
Institutional Holdings
Institutions: 16
Institutional Holdings: 688.37K
% Owned: 5.46%
Shares Outstanding: 12.62M
TypeInstitutionsShares
Increased
4
33.13K
New
4
122.73K
Decreased
2
35.33K
Sold Out
2
550.95K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Non-Executive Chairman
Iain Ross
Chief Executive Officer/Executive Director
James Garner
Other
Gordon Hirsch
Other
Lilischkis Kimberley
Other
Peng Leong
Other
Stephen Palmer
Other
Justine Stehn
Secretary
Kate Hill
Non-Executive Director
Bryce Carmine
Non-Executive Director
Steven Coffey
No Data
About KZIA
Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.

Webull offers kinds of Kazia Therapeutics Ltd (ADR) stock information, including NASDAQ:KZIA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KZIA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KZIA stock methods without spending real money on the virtual paper trading platform.